Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
Clinic for Radiology, University Hospital Muenster, Muenster, Germany.
Cardiovasc Intervent Radiol. 2023 Jan;46(1):142-151. doi: 10.1007/s00270-022-03296-8. Epub 2022 Oct 19.
Arteriovenous malformations (AVMs) as rare diseases are diagnostically and therapeutically challenging. Due to the limited evidence regarding treatment outcome, prospective data are needed on how different treatment regimens affect outcome. The aims of this prospective trial are to determine effectiveness, safety, and clinical outcome of multimodal treatment in patients with extracranial AVMs.
After clinical and magnetic resonance imaging (MRI)-based diagnosis and informed consent, 146 patients (> 4 years and < 70 years) undergoing multimodal therapy in tertiary care vascular anomalies centers will be included in this prospective observational trial. Treatment options include conservative management, medical therapy, minimally invasive image-guided procedures (embolization, sclerotherapy) and surgery as well as combinations of the latter. The primary outcome is the patient-reported QoL 6 months after completion of treatment using the short form-36 health survey version 2 (SF-36v2) and the corresponding short form-10 health survey (SF-10) for children. In addition, clinical presentation (physician-reported signs), MRI imaging (radiological assessment of devascularization), recurrence rate, and therapeutic safety will be analyzed. Further follow-up will be performed after 12, 24, and 36 months. Moreover, liquid biopsies are being obtained from peripheral blood at multiple time points to investigate potential biomarkers for therapy response and disease progression.
The APOLLON trial is a prospective, multicenter, observational open-label trial with unequal study groups to generate prospective evidence for multimodal treatment of AVMs. A multicenter design with the potential to assess larger populations will provide an increased understanding of multimodal therapy outcome in this orphan disease.
German Clinical Trials Register (identification number: DRKS00021019) https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021019 .
动静脉畸形(AVM)作为罕见疾病,在诊断和治疗方面具有挑战性。由于治疗结果的证据有限,需要有前瞻性数据来了解不同治疗方案如何影响结果。本前瞻性试验的目的是确定多模态治疗对颅外 AVM 患者的有效性、安全性和临床结果。
在临床和磁共振成像(MRI)诊断并获得知情同意后,将纳入 146 名(年龄>4 岁且<70 岁)在三级血管畸形中心接受多模态治疗的患者,进行这项前瞻性观察性试验。治疗选择包括保守治疗、药物治疗、微创影像引导下的程序(栓塞、硬化治疗)和手术,以及后两者的组合。主要结果是治疗完成后 6 个月时患者报告的生活质量,使用简短形式 36 健康调查版本 2(SF-36v2)和儿童的简短形式 10 健康调查(SF-10)进行评估。此外,还将分析临床表现(医生报告的体征)、MRI 成像(去血管化的影像学评估)、复发率和治疗安全性。进一步的随访将在 12、24 和 36 个月后进行。此外,还将从外周血中多次获取液体活检,以研究潜在的治疗反应和疾病进展的生物标志物。
APOLLON 试验是一项前瞻性、多中心、观察性、开放标签试验,研究组之间不均衡,旨在为 AVM 的多模态治疗提供前瞻性证据。具有评估更大人群潜力的多中心设计将提高对这种孤儿病多模态治疗结果的理解。
德国临床试验注册处(识别号:DRKS00021019)https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021019。